Pancreatic ductal adenocarcinoma (PDAC) is one of the deadliest types of 
malignancy. Via a broad stimulation of the immune system, PDAC activates both 
antitumor immune responses and immunosuppressive mechanisms. We propose that new 
immunotherapeutic strategies for the management of PDAC should be designed to 
specifically neutralize the immunosuppressive tumor microenvironment.